LBRX - LB Pharmaceuticals Inc Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 15.62 0.84 (5.38%) | --- | --- | --- | --- | 0.84 (5.38%) | --- | --- |
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Category:
/stock/categories/na
Market Period:
PreMarket
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 53.51
- VWAP:
- 16.4
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|